OptimizeRx Corporation (OPRX)

CTI BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	231	90	260	288	1,104	471
Market Cap Growth	-27.40%	-65.54%	-9.86%	-73.89%	134.43%	223.42%
Enterprise Value	247	109	196	210	1,019	459
Last Close Price	12.50	4.86	14.31	16.80	62.11	31.16
PE Ratio	-	-	-	-	2919.14	-
Forward PE	24.44	18.07	47.18	39.84	106.12	97.38
PS Ratio	2.43	0.97	3.63	4.61	18.01	10.87
PB Ratio	1.99	0.77	2.05	2.29	8.40	9.42
P/TBV Ratio	258.31	146.04	-	3.19	10.41	20.37
P/FCF Ratio	35.41	18.74	-	27.26	1763.84	-
P/OCF Ratio	34.84	18.31	-	27.05	1520.12	-
PEG Ratio	-	2.94	2.94	2.66	2.12	1.56
EV/Sales Ratio	2.62	1.18	2.75	3.36	16.63	10.60
EV/EBITDA Ratio	241.85	-	-	-	438.00	709.90
EV/EBIT Ratio	-	-	-	-	2821.85	-
EV/FCF Ratio	37.90	22.84	-	19.83	1628.49	-
Debt / Equity Ratio	0.28	0.28	0.29	0.00	0.00	0.01
Debt / EBITDA Ratio	25.79	-	-	-	0.13	0.50
Debt / FCF Ratio	5.03	6.95	-	0.02	0.52	-
Asset Turnover	0.55	0.52	0.45	0.45	0.61	0.74
Quick Ratio	2.69	2.77	2.86	11.47	11.69	2.83
Current Ratio	2.82	2.89	3.04	11.74	12.29	3.28
Return on Equity (ROE)	-12.91%	-16.51%	-13.91%	-8.88%	0.42%	-4.66%
Return on Assets (ROA)	-1.20%	-2.19%	-5.21%	-5.57%	0.22%	-1.42%
Return on Capital (ROIC)	-1.34%	-2.48%	-5.72%	-5.95%	0.25%	-1.73%
Return on Capital Employed (ROCE)	-	-	-	-	0.30%	-
Earnings Yield	-6.67%	-22.46%	-6.76%	-3.97%	0.03%	-0.47%
FCF Yield	2.82%	5.34%	-2.82%	3.67%	0.06%	-1.35%
Buyback Yield / Dilution	-5.60%	-6.82%	3.71%	-0.53%	-19.30%	-10.76%

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q